Aqr Capital Management LLC Catalyst Pharmaceuticals, Inc. Transaction History

Aqr Capital Management LLC

$71.5 Billion
Q3 2024

A detailed history of Aqr Capital Management LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Aqr Capital Management LLC holds 459,352 shares of CPRX stock, worth $9.94 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

459,352

Previous 488,386 5.94%

Holding current value

$9.94 Million

Previous $7.57 Million 20.7%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$15.19 - $21.35 $441,026 - $619,875	-29,034 Reduced 5.94%	459,352 $9.13 Million
Q2 2024 Aug 14, 2024	BUY	$14.68 - $16.92 $3.34 Million - $3.85 Million	227,321 Added 87.07%	488,386 $7.57 Million
Q1 2024 May 15, 2024	SELL	$13.18 - $17.11 $1.08 Million - $1.4 Million	-81,736 Reduced 23.84%	261,065 $4.16 Million
Q4 2023 Feb 14, 2024	SELL	$11.78 - $17.29 $1.58 Million - $2.32 Million	-133,999 Reduced 28.1%	342,801 $5.76 Million
Q3 2023 Nov 14, 2023	SELL	$11.69 - $15.02 $1.94 Million - $2.5 Million	-166,194 Reduced 25.85%	476,800 $5.57 Million
Q2 2023 Aug 14, 2023	BUY	$11.5 - $18.08 $4.36 Million - $6.85 Million	378,770 Added 143.35%	642,994 $8.64 Million
Q1 2023 May 15, 2023	BUY	$14.34 - $21.05 $513,285 - $753,463	35,794 Added 15.67%	264,224 $4.38 Million
Q4 2022 Feb 14, 2023	SELL	$12.25 - $19.5 $2.11 Million - $3.36 Million	-172,201 Reduced 42.98%	228,430 $4.25 Million
Q3 2022 Nov 14, 2022	SELL	$7.06 - $15.52 $613,584 - $1.35 Million	-86,910 Reduced 17.83%	400,631 $5.14 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $8.57 $460,951 - $634,085	73,989 Added 17.89%	487,541 $3.42 Million
Q1 2022 May 16, 2022	SELL	$5.31 - $8.31 $130,206 - $203,769	-24,521 Reduced 5.6%	413,552 $3.43 Million
Q4 2021 Feb 14, 2022	SELL	$5.21 - $7.45 $194,041 - $277,467	-37,244 Reduced 7.84%	438,073 $2.97 Million
Q3 2021 Nov 15, 2021	BUY	$4.85 - $6.04 $732,927 - $912,758	151,119 Added 46.61%	475,317 $2.52 Million
Q2 2021 Aug 16, 2021	SELL	$4.29 - $6.05 $1.71 Million - $2.42 Million	-399,455 Reduced 55.2%	324,198 $1.86 Million
Q1 2021 May 17, 2021	SELL	$3.45 - $4.69 $930,734 - $1.27 Million	-269,778 Reduced 27.16%	723,653 $3.34 Million
Q4 2020 Feb 16, 2021	BUY	$2.97 - $3.83 $427,380 - $551,133	143,899 Added 16.94%	993,431 $3.32 Million
Q3 2020 Nov 16, 2020	SELL	$2.97 - $5.08 $165,464 - $283,016	-55,712 Reduced 6.15%	849,532 $2.52 Million
Q2 2020 Aug 17, 2020	SELL	$3.48 - $5.05 $1.07 Million - $1.55 Million	-307,205 Reduced 25.34%	905,244 $4.18 Million
Q1 2020 May 15, 2020	BUY	$2.61 - $5.21 $201,766 - $402,759	77,305 Added 6.81%	1,212,449 $4.67 Million
Q4 2019 Feb 14, 2020	BUY	$3.67 - $5.7 $3.55 Million - $5.52 Million	968,574 Added 581.48%	1,135,144 $4.26 Million
Q3 2019 Nov 14, 2019	SELL	$3.89 - $7.43 $442,946 - $846,039	-113,868 Reduced 40.6%	166,570 $884,000
Q2 2019 Aug 14, 2019	BUY	$2.7 - $6.11 $588,170 - $1.33 Million	217,841 Added 348.01%	280,438 $1.08 Million
Q1 2019 May 14, 2019	SELL	$2.11 - $5.33 $162,986 - $411,715	-77,245 Reduced 55.24%	62,597 $319,000
Q4 2018 Feb 14, 2019	SELL	$1.92 - $3.62 $112,807 - $212,689	-58,754 Reduced 29.58%	139,842 $268,000
Q3 2018 Nov 15, 2018	SELL	$2.81 - $3.78 $496,808 - $668,304	-176,800 Reduced 47.1%	198,596 $751,000
Q2 2018 Aug 14, 2018	SELL	$2.26 - $3.84 $965,700 - $1.64 Million	-427,301 Reduced 53.23%	375,396 $1.17 Million
Q1 2018 May 15, 2018	BUY	$2.39 - $4.01 $1.11 Million - $1.87 Million	466,119 Added 138.49%	802,697 $1.92 Million
Q4 2017 Feb 14, 2018	SELL	$2.51 - $4.4 $40,280 - $70,611	-16,048 Reduced 4.55%	336,578 $1.32 Million
Q3 2017 Nov 14, 2017	BUY	$2.4 - $2.94 $846,302 - $1.04 Million	352,626	352,626 $889,000

Others Institutions Holding CPRX

# of Institutions

327

Shares Held

94.6M

Call Options Held

19.1K

Put Options Held

51.1K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.23B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.

Account

Aqr Capital Management LLC Catalyst Pharmaceuticals, Inc. Transaction History